| Jarrell Dupree Nesmith, DO | |
|
2400 Boiling Springs Rd, Boiling Springs, SC 29316-5304 | |
| (864) 599-0731 | |
| (864) 599-0791 |
| Full Name | Jarrell Dupree Nesmith |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 2400 Boiling Springs Rd, Boiling Springs, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407267263 | NPI | - | NPPES |
| L36729 | Medicaid | SC | |
| PENDING | Medicaid | SC | |
| SCA7316121 | Other | SC | MEDICARE PIN |
| SCA7317628 | Other | SC | MEDICARE PIN |
| SCA731J577 | Other | SC | MEDICARE PIN |
| SCA7316067 | Other | SC | MEDICARE PIN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 36729 (South Carolina) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | (South Carolina) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Greenville, SC | Home health agency |
| Prisma Health Greenville Memorial Hospital | Greenville, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prisma Health University Medical Group | 8325950983 | 2201 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
A Utah state law that requires convicted commercial sex workers and solicitors of commercial sex to be tested for HIV and makes sex work and solicitation a "felony offense for repeat offenders who were aware they had tested positive for HIV" could "deter" sex work, but it is "not happening" because the law is not enforced, a Salt Lake Tribune editorial says (Salt Lake Tribune, 5/5).
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.
New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.
› Verified 2 days ago
| Entity Name | Prisma Health University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295763217 PECOS PAC ID: 8325950983 Enrollment ID: O20031103000238 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
A Utah state law that requires convicted commercial sex workers and solicitors of commercial sex to be tested for HIV and makes sex work and solicitation a "felony offense for repeat offenders who were aware they had tested positive for HIV" could "deter" sex work, but it is "not happening" because the law is not enforced, a Salt Lake Tribune editorial says (Salt Lake Tribune, 5/5).
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.
New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.
› Verified 2 days ago
| Entity Name | Regenesis Organization Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457745952 PECOS PAC ID: 8022928001 Enrollment ID: O20170127000968 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
A Utah state law that requires convicted commercial sex workers and solicitors of commercial sex to be tested for HIV and makes sex work and solicitation a "felony offense for repeat offenders who were aware they had tested positive for HIV" could "deter" sex work, but it is "not happening" because the law is not enforced, a Salt Lake Tribune editorial says (Salt Lake Tribune, 5/5).
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.
New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.
› Verified 2 days ago
| Entity Name | Regenesis Organization Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558946376 PECOS PAC ID: 8022928001 Enrollment ID: O20220630000562 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
A Utah state law that requires convicted commercial sex workers and solicitors of commercial sex to be tested for HIV and makes sex work and solicitation a "felony offense for repeat offenders who were aware they had tested positive for HIV" could "deter" sex work, but it is "not happening" because the law is not enforced, a Salt Lake Tribune editorial says (Salt Lake Tribune, 5/5).
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.
New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jarrell Dupree Nesmith, DO 300 E Mcbee Ave Fl 4, Greenville, SC 29601-2842 Ph: () - | Jarrell Dupree Nesmith, DO 2400 Boiling Springs Rd, Boiling Springs, SC 29316-5304 Ph: (864) 599-0731 |
News Archive
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular risk factors.
NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
A Utah state law that requires convicted commercial sex workers and solicitors of commercial sex to be tested for HIV and makes sex work and solicitation a "felony offense for repeat offenders who were aware they had tested positive for HIV" could "deter" sex work, but it is "not happening" because the law is not enforced, a Salt Lake Tribune editorial says (Salt Lake Tribune, 5/5).
Nuvo Research Inc., a drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that PENNSAID(R) (diclofenac sodium topical solution) 1.5% w/w, is now available by prescription in U.S. pharmacies.
New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.
› Verified 2 days ago
Deborah Jo Taylor, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 240 Laurelwood Dr, Boiling Springs, SC 29316 Phone: 864-431-4666 | |
Dr. Gregory L Gibson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3941 Highway 9, Boiling Springs, SC 29316 Phone: 864-560-3650 Fax: 864-560-3675 | |
Gertrude Po Cotiaux, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Boiling Springs Rd Ste A, Boiling Springs, SC 29316 Phone: 864-599-0731 Fax: 864-599-0791 | |
Lauren Casey Beattie, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 107 Parris Bridge Rd, Boiling Springs, SC 29316 Phone: 864-274-3006 | |
Saiward Whitener Glenn, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3941 Highway 9, Boiling Springs, SC 29316 Phone: 864-560-3650 Fax: 864-560-3675 | |
Melinda Sue Durham, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2212 Old Furnace Road, Boiling Springs, SC 29316 Phone: 864-578-9735 Fax: 864-578-7098 |